TikTok launches TikTok AI Alive, a new image-to-video tool
TikTok is launching its first image-to-video AI feature, the company announced on Tuesday. The new feature is called "TikTok AI Alive" and allows users to turn static photos into videos within TikTok Stories.
The feature is only accessible via TikTok's Story Camera and uses AI to create short-form videos with "movement, atmospheric and creative effects," TikTok says.
For instance, if your static photo features a sky, clouds, and the ocean, TikTok could turn the photo into a video where the sky gradually shifts hues, the clouds start to drift, and you hear the sound of waves crashing. Or, you could animate a group selfie that highlights gestures and expressions.
The launch of the new image-to-video features comes a few years after TikTok introduced an in-app text-to-image AI generator. While both Instagram and Snapchat also offer text-to-image AI features for creators, TikTok is now taking a step further by offering its users the ability to create videos from images. It's worth noting that Snapchat has said it will soon allow creators to generate AI videos from images.
AI Alive stories will have an AI-generated label to notify users that the content was created with AI. Plus, this content will have C2PA metadata embedded, which is a technical standard that helps others identify that the video is AI-generated, even if it's downloaded and shared beyond TikTok.
"We are always building with safety in mind, and the same goes for our AI innovations," TikTok said in a blog post. "As this technology enables new forms of creative expression, it undergoes multiple trust and safety checks to protect our community. To help prevent people from creating content that violates our policies, moderation technology reviews the uploaded photo and written AI generation prompt as well as the AI Alive video before it's shown to the creator."
TikTok notes that people can report videos that they think break the app's rules, and that the app conducts a final safety check once a creator shares an AI Alive story.
Creators can create an AI Alive video by opening the Story Camera and tapping the blue plus button on the top of the Inbox page or Profile page. From there, you can choose a photo from your Story Album. You will then see the AI Alive icon on the right side toolbar on the photo edit page.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Raymond James Lifts Coherent Corp. (COHR)'s Stock Price Target to $96, Maintains Strong Buy Rating
Raymond James analyst Simon Leopold on Wednesday raised Coherent Corp. (NYSE:COHR)'s stock price target to $96 from $91, while maintaining the Strong Buy rating for its shares. The revision followed Coherent Corp. (NYSE:COHR)'s Analyst and Investor Day earlier in the day, in which the company shared its long-term growth targets that surpassed both Raymond James' and the broader market's expectations. A row of precision industrial lasers in action, cutting the most intricate of shapes. Coherent Corp. (NYSE:COHR)'s management outlined its goals, such as aiming for a gross margin greater than 42% and an operating margin above 24%, indicating that by 2028, the company could achieve an EPS of around $8-9, which will be a substantial increase from forecasts of under $4 in fiscal 2025. Considering these ambitious targets, Raymond James lifted the stock's target price to account for the anticipated gross margin expansion and growth in the industrial laser sector. Moreover, on May 7, Coherent Corp. (NYSE: COHR) reported impressive results for the third quarter of fiscal 2025, with revenue increasing 24% year-over-year to $1.5 billion, driven by strong demand for AI-related data centers. Earnings per share were posted at $0.91, beating estimates by five cents. While we acknowledge the potential of COHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COHR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: ChatGPT Stock Advice: Top 12 Stock Recommendations and 10 Cheap Rising Stocks to Buy Right Now. Disclosure: None.
Medscape
36 minutes ago
- Medscape
AI Tool Linked to Fewer Recurrent Events After Stroke
HELSINKI, Finland — An artificial intelligence (AI)–based clinical decision support system helped doctors make decisions in the treatment of acute ischemic stroke and was associated with a significant reduction in recurrent vascular events in a new, randomized trial. The AI system integrated clinician input with data from the hospital records and imaging of more than 20,000 patients in China to help guide patient management around stroke etiology and secondary prevention. The trial represents a strong case for the future role of AI in stroke care, said Study Chair, Li Zhang, MD, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 'By harnessing AI to deliver rapid, evidence-based guidance, we've shown that decision support can move beyond theory into practice — improving both how we treat acute strokes and the lives of our patients.' However, experts not involved in the study noted that the research is based on Chinese stroke guidelines — which differ from guidelines in the United States and United Kingdom — and would need to be replicated in the West before use. Zhang presented the results of the GOLDEN BRIDGE II trial on May 22 at the European Stroke Organization Conference (ESOC) 2025. A Test of AI in Stroke Management Rapid and accurate decision-making is critical in acute stroke management, and AI tools offering automated imaging analysis, stroke subtype classification, and guideline-based treatment recommendations, hold promise for standardizing care and improving outcomes, Zhang noted. The GOLDEN BRIDGE II trial was designed to test this hypothesis in a real-world, multicenter setting. The trial, which had a cluster randomized design, was conducted from January 2021 to June 2023 in 77 hospitals in China. The hospitals were randomized to use the AI support system or to continue usual care. The AI system provided automated MRI lesion detection and lesion characteristics analysis, algorithmic classification of stroke etiology and pathogenesis, with real-time, guideline-based recommendations for secondary prevention. The trial included 21,603 patients with acute ischemic stroke (median age, 67 years; 35% women), with 96% completing a 12-month follow-up. The primary endpoint was the occurrence of new vascular events (composite of ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death) at 3 months after stroke onset. A 'Strong Case' Results showed that patients for whom the AI model was used had significantly fewer recurrent vascular events at all three time points evaluated. Rates of recurrent vascular events in the intervention group vs the control group were 2.9% vs 3.9% (adjusted hazard ratio [aHR], 0.71; P < .001) at 3 months; 3.4% vs 4.8% (aHR, 0.70; P < .001) at 6 months; and 4.0% vs 5.5% (aHR, 0.70; P < .001) at 12 months. The use of the AI tool was also associated with a lower all-cause mortality at 6 months (2.0% vs 2.3%; aHR, 0.78; P = .007) and at 12 months (3.0% vs 3.5%; aHR 0.77; P < .001). In addition, patients at the hospitals using the AI tool were more likely to achieve a higher composite acute ischemic stroke quality score (91.4 % vs 89.7 %; odds ratio, 1.26; P < .001). A potential limitation of the study was the cluster randomized design, which could allow variations in care between hospitals to influence the results. But Zhang concluded that the trial represents a strong case for the future role of AI in stroke care, saying that the findings 'support wider adoption of AI-driven decision support to optimize acute stroke care and patient outcomes globally.' Not Ready for Routine Clinical Use Commenting on the findings during a discussion on the GOLDEN BRIDGE II trial, Carlos Molina, MD, head of Neurology at Vall d'Hebron Hospital, Barcelona, Spain, noted several study strengths, including the large study cohort and the clinical and technological validation of the sophisticated AI system used in the trial. 'This is an important step,' he added, 'but there are always concerns when we think about trying to integrate AI into clinical practice.' Georgios Tsivgoulis, MD, professor of neurology at the National and Kapodistrian University of Athens, Athens, Greece, noted that although there was a substantial reduction in vascular events and recurrent strokes in the intervention group, the mechanisms that led to this reduction were not clear. 'How did the AI improve clinical practice? Was it through imaging, was it because of better adherence to the Chinese stroke guidelines or was it related to better stroke subtype classification and perhaps treatment individualization? I would like to see more information about the step between the AI implementation and the event reduction results,' he commented. Karin Klijn, professor and chair of neurology at Radboud University Medical Center, Nijmegen, the Netherlands, said the improvement in recurrent events appeared to be driven by the imaging. 'But we didn't hear any details, and we need to see more details so we can see where improvements can be made.' 'However, this was an impressive study in that it involved more than 70 hospitals and more than 20,000 patients. I think AI will help us to achieve the same level of confidence for all the images we have to examine and decisions we have made. I see great potential for this technology,' Klijn added. The trial would also need to be replicated in the Western world for the AI tool to be used in Europe or North America, Tsivgoulis said. 'The GOLDEN BRIDGE II trial is based on the Chinese stroke guidelines which are substantially different from European and US stroke guidelines,' he pointed out. 'It would need to be replicated in Europe and North America using standardized European Stroke Organization and American Stroke Association guidelines to see if this huge beneficial effect can be replicated in Western patients.' Molina agreed, adding that 'the data sources used to train this model are critical to avoid bias that AI can amplify.' In the future, more complex large language models will be available that involve real time interaction with the user and include reinforcing learning, Molina added. 'This prototype is evolving and interaction with the user is critical. There is a lot to learn about that. But this is the first step,' he said. Also commenting, Alastair Webb, MD, clinical reader in stroke medicine at Imperial College London, London, England, also had questions on how it could be implemented in practice. 'This study was designed a few years ago and has taken years to produce these results. How do we keep the algorithm updated and incorporate the continuous changes in clinical practice that occur? We can't do a trial for every update. So we are going to have to integrate this technology into our systems with some sort of real time method of assessing whether every new evolution doesn't cause harm, doesn't make the wrong decision in a large language model.'
Business Wire
42 minutes ago
- Business Wire
Onc.AI to Present Breakthrough Deep Learning Radiomic Biomarker Results at 2025 ASCO Annual Meeting
CHICAGO--(BUSINESS WIRE)-- a digital health company developing AI-powered oncology clinical management solutions, today announced that new validation study results from research collaborations with Pfizer, Baylor Scott & White and the University of Rochester Medical Center will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30–June 3, 2025, in Chicago, IL. Deep learning radiomics to transform oncology clinical development and improve upon RECIST 1.1 (#better_recist) Share poster presentation showcases its FDA-breakthrough designated deep learning radiomics model, Serial CTRS, which evaluates changes across routine CT scans over time to predict overall survival in late-stage non–small cell lung cancer (NSCLC) and other solid tumor types. In collaboration with Baylor Scott & White and Pfizer, Serial CTRS has demonstrated: Superior prediction of overall survival (OS): Hazard ratios (HRs) for OS improvement and stratification exceed those of the conventional imaging approach (RECIST 1.1). Generalizability across real-world and clinical trial cohorts: Robust performance in both routine real-world datasets and a Pfizer-sponsored PD-1 checkpoint inhibitor trial. Actionable insights for early treatment adaptation: Dynamic monitoring identifies non-responders months before conventional criteria would signal poor prognosis. At the ASCO Innovation Hub (IH13), will share latest results from its pipeline of deep learning radiomic models to customers and partners spanning medical oncologist investigators and biopharma companies looking to accelerate oncology clinical development. Program Highlights Poster Presentation: Abstract #253138: Validation of Serial CTRS for Early Immunotherapy Response Prediction in Metastatic NSCLC – Presenter: Ronan Kelly, MD, Baylor Scott & White Date & Time: June 1, 2025; 9:00 am–12:00 pm CDT Location: Hall A, Poster Board 325 Abstract #251996: Retrospective Single-Institution Application of a Deep Learning–Based Radiomic Score in Metastatic NSCLC: Potential Impact on First-Line Treatment Decisions – Lead Author: Nicholas Love, MD, University of Rochester Abstract #245837: Image Harmonization for PD-(L)1 Immune Checkpoint Inhibitor Response Prediction Using Deep Learning Radiomic Features in Advanced NSCLC – Lead Author: Taly Gilat-Schmidt, PhD, 'These strong validation study results spanned both RWD and a pharma-sponsored clinical trial. Serial CTRS could represent a high-potential tool for medical oncologists and for optimizing pharma clinical development,' said Dr. Ronan Kelly, MD, Director of Oncology at the Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas Texas 'Our retrospective study highlights how Deep Learning Radiomic baseline score can be extremely helpful to medical oncologists as a prognostic marker for first line mutation negative NSCLC patients,' added Arpan Patel, MD and Associate Professor of Medical Oncology at the University of Rochester Medical Center. About is a digital health company developing AI-driven oncology clinical management solutions using advanced Deep Learning applied to routine diagnostic images. The company's platform is applied at the point of care by medical oncologists and is also leveraged by global pharmaceutical leaders to accelerate oncology drug development. is backed by premier institutional investors, including Blue Venture Fund, Action Potential Venture Capital (GSK) and MassMutual Alternative Investments. is also supported by the National Cancer Institute SBIR program (1R44CA291456-01A1). For more information, please visit:
